T0	Participants 81 154	patients with epithelial ovarian cancer and relation to TP53 gene status.
T1	Participants 579 629	45 ovarian cancer patients randomized to treatment
T2	Participants 729 797	38 patients with clinically evaluable disease after initial surgery.